Rituximab Therapy for Severe Cutaneous Leukocytoclastic Angiitis Refractory to Corticosteroids, Cellcept and Cyclophosphamide
نویسندگان
چکیده
منابع مشابه
Rituximab Therapy for Severe Cutaneous Leukocytoclastic Angiitis Refractory to Corticosteroids, Cellcept and Cyclophosphamide
We report our clinical experience with rituximab in the treatment of 2 patients with idiopathic cutaneous angiitis who relapsed after treatment with high-dose corticosteroids and cyclophosphamide. A 39-year-old woman and a 51-year-old man presented with ulcerating maculopapular rash in both lower limbs which relapsed 6 months after treatment with a combination of high-dose corticosteroids and c...
متن کاملInfliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
Cutaneous vasculitis can be classified as primary or idiopathic; or secondary, when it presents as a manifestation of connective tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive to supportive measures and nonsteroidal anti-inflammatory drugs, potent immunosuppressants are sometimes required for the management of t...
متن کاملCutaneous leukocytoclastic vasculitis associated with levofloxacin therapy
Many cases of cutaneous vasculitis are drug-induced with histology revealing leukocytoclastic vasculitis (LCV). We present a case of levofloxacin-associated LCV successfully treated with prednisone and cessation of the offending drug. Although case reports describe a link between LCV and older fluoroquinolones, such as ciprofloxacin and ofloxacin, recent reports have implicated the newer fluoro...
متن کامل[Cyclophosphamide pulse therapy for refractory rheumatic diseases].
We studied the efficacy of cyclophosphamide pulse therapy (CYP) for refractory rheumatic diseases except for lupus nephritis. Thirty-five patients were included in all, that is 9 patients with systemic lupus erythematosus (SLE), 10 with rheumatoid arthritis (RA), 7 with polymyositis/dermatomyositis (PM/DM), 2 with progressive systemic sclerosis (PSS), 2 with anti-phospholipid antibody syndrome ...
متن کاملAdditional antibody suppression from rituximab added to conventional therapy in severe, refractory anti-GBM nephritis
of worsening renal insufficiency. Serial SUPCR demonstrated that the proteinuria decreased after each cycle of bortezomib followed by a rebound during each 10-day rest period. The changes in the SUPCR grossly paralleled changes in SFLC levels. A bone marrow examination showed extensive replacement by multiple myeloma, confirming treatment resistance. Patient 4 had three consecutive SFLCA in whi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports in Dermatology
سال: 2013
ISSN: 1662-6567
DOI: 10.1159/000350559